AA方案治疗CML加速急变期疗效分析

The combination or arabinsyl cytosine and aclarubicin as treatment for accelerated phase of chronic myelogenous leukimia and blast phase of chronic myelogenous leukemia: a analysis for clinical response.

目的 观察AA方案(阿糖胞苷、阿克拉霉素)治疗CML加速期、急变期疗效及毒副作用,评价该方案在CML治疗中的地位及推广价值。方法 对70例CML加速急变期患者进行140例次AA方案化疗。结果 完全缓解38例,部分缓解16例,无效16例,总有效率76.0％,本方案治疗无相关死亡。结论 AA方案治疗CML加速急变期有较高的缓解率,未发生严重致死性毒副作用,值得临床推广应用。

[Abstract] Objective To observe the efficacy and side effects of the combination of Arabinsyl cytosine (Ara-c) and Aclarubicin (Acla) as treatment for accelerated phase of chronic Myelogenous leukemia (CML-Bp) .To explore the clinical implication of the combination of Ara-c and Acla. Methods Seventy patients with CML-Ap and CML-Bp were treated with the combination of Ara-c and Acla. One hundred and forty case-times were treated with the combination of Ara-c and Acla. Results The complete remission(CR) patients were thirty- eight, the partial remission (PR) patients were sixteen, the non-remission (NR) patients were sixteen. The total response rate was 76% .No patients died because of the combination of Ara-c and Acla as treatment .Conclusion The combination of Ara-c and Acla as treatment for CML-Ap and CML-Bp has fairly good remission rates and serious side effects to death doesn' t happen. So the combination of Ara-c and Acla can be applied in the treatment of CML-Ap and CML-Bp.